Device Trial Radar · NCT07332182
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
Last checked: Nov 21, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Apr 30, 2031
Study completion Apr 30, 2031
Sponsor
- Lead sponsor
- Fin-Ceramica Faenza SpaNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location. The evaluation will be performed through clinical, subjective and objective assessments.
Conditions
- Osteochondral Lesions of the Knee Joint
- Osteochondritis Dissecans (OCD)
- Early Osteoarthritis
Interventions
osteochondral scaffold implantDevice
three layered biomimetic osteochondral scaffold implant for osteochondral lesions of the knee
SSOCProcedure
Debridement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Superiority of MaioRegen Prime vs DebridementTime frame: baseline, 24 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Grossmont Orthopaedic Medical Group
La Mesa, California · Not yet recruiting
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.